Clinical Research Details

Clinical Research

MBPS205: A Phase 2b, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with BPS804

Study Description

The purpose of this study is to learn about the effects of a research drug, BPS804, to find the best dose for treating osteogenesis imperfecta Type I, III or IV and to see how well BPS804 is tolerated.


Principal Investigator
Kent R. Wehmeier, M.D.

Sub Investigator
Marilu M. Jurado Flores, M.D.